Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Catalyst Biosciences, a developer of biopharmaceuticals that harness catalytic power of engineered proteases, has raised $40.4 million in a series C financing round.
Subscribe to our email newsletter
New investor Essex Woodlands Health Ventures led the round, with participation from existing investors Burrill & Company, HealthCare Ventures, Johnson & Johnson Development, Morgenthaler Ventures, Novartis BioVentures and Sofinnova Ventures.
In conjunction with the financing, Jeff Himawan from Essex Woodlands will join Catalyst Biosciences’s board of directors.
Nassim Usman, CEO of Catalyst Biosciences, said: “We are very pleased to have received such strong support from our investors and to add Essex Woodlands to this premier group.
“The financing provides us with several years of funding that will allow us to build our pipeline of Alterase therapeutics including advancing our lead protease, CB 813, an improved Factor VIIa product for the treatment of acute bleeding in hemophiliacs, through Phase I/II proof-of-concept studies in patients.”